Financings in Brief: Selfcare
This article was originally published in The Gray Sheet
Executive Summary
Selfcare: Initial public offering of 1.3 mil. shares priced at $8.50 per share nets the firm $10.3 mil. An overallotment option of 195,000 shares is still outstanding. The Waltham, Massachusetts-based maker of "self-test" diagnostics for diabetes, women's health and infectious diseases plans to use the proceeds for R&D, working capital and "other general corporate purposes, including the possible repayment of certain indebtedness and possible acquisitions," the firm states. In a registration statement for the offering, filed with the Securities and Exchange Commission in May, Selfcare projected an offering of 2.7 mil. shares for $12 each ("The Gray Sheet" June 17, p. 26). The issue will trade on the American Stock Exchange under the symbol "SLF"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.